经活检证实的非酒精性脂肪性肝病患者的临床结局:一项多中心注册登记队列研究
该多中心注册登记回顾性队列研究纳入1398例经活检证实的亚洲非酒精性脂肪性肝病患者,中位随访4.6年。结果显示肝脏相关死亡是主要死因,肝纤维化分期与肝脏相关事件独立相关,但与全因死亡率无关。
要点
- 中位随访4.6年,肝脏相关死亡是经活检证实NAFLD患者的主要死因。
- 肝纤维化分期与肝脏相关事件独立相关,但与全因死亡率无关。
- 随访期间37例发生肝细胞癌,68例发生非肝脏癌症。
核心结论
- 在经活检证实的亚洲非酒精性脂肪性肝病患者中,肝脏相关死亡是主要死因。
- 肝纤维化分期与肝脏相关事件独立相关,但在调整混杂因素(如脂肪性肝炎的组织学特征)后与全因死亡率无关。
研究设计与样本
- 本研究为多中心注册登记回顾性队列研究,名为CLIONE(亚洲非酒精性脂肪性肝病临床结局),纳入1398例患者。
- 中位随访期为4.6年(范围0.3-21.6年),共计8874人年随访。
主要发现
- 随访期间47例死亡,1例接受原位肝移植;主要死因为非肝脏癌症(n=10)。
- 肝脏相关主要死因包括肝衰竭(n=9)、肝细胞癌(n=8)和胆管细胞癌(n=4)。
- 随访期间37例发生肝细胞癌,31例发生心血管疾病,68例发生非肝脏癌症(主要为乳腺、胃和结直肠)。
- 肝脏特异性死亡率为2.34/1000人年(95%CI 1.52-3.58),全因死亡率为5.34/1000人年(95%CI 4.02-7.08),肝细胞癌发生率为4.17/1000人年(95%CI 3.02-5.75)。
关键数值与推荐
- 肝纤维化分期与肝脏相关事件独立相关,但与全因死亡率无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: There are no detailed reports of clinical outcomes in Asian patients with nonalcoholic fatty liver disease (NAFLD) who undergo liver biopsy. We aimed to investigate the clinical outcomes of a large cohort of Asian patients with biopsy-proven NAFLD and evaluate the specific effects of nonalcoholic steatohepatitis and fibrosis stage. METHODS: This multicenter registry-based retrospective cohort study, called the CLIONE (Clinical Outcome Nonalcoholic Fatty Liver Disease) in Asia, included 1398 patients. RESULTS: The median follow-up period was 4.6 years (range, 0.3-21.6 years), representing a total of 8874 person-years of follow-up. During that time, 47 patients died, and 1 patient underwent orthotopic liver transplantation. The leading cause of death was nonhepatic cancer (n = 10). The leading causes of liver-related death were liver failure (n = 9), hepatocellular carcinoma (HCC) (n = 8), and cholangiocellular carcinoma (n = 4). During follow-up, 37 patients developed HCC, 31 developed cardiovascular disease, and 68 developed nonhepatic cancer (mainly breast, stomach, and colon/rectum). Among our cohort of patients with NAFLD, liver-specific mortality was 2.34/1000 person-years (95% confidence interval [CI], 1.52-3.58), overall mortality was 5.34/1000 person-years (95% CI, 4.02-7.08), and HCC incidence was 4.17/1000 person-years (95% CI, 3.02-5.75). Liver fibrosis was independently associated with liver-related events but not overall mortality. CONCLUSIONS: Liver-related mortality was the leading cause of mortality in Asian patients with biopsy-confirmed NAFLD. Although fibrosis stage was independently associated with liver-related events, it was not associated with overall mortality after adjusting for confounders, such as histologic features of steatohepatitis.
引用
- Fujii H, Iwaki M, Hayashi H, et al. Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study. Clin Gastroenterol Hepatol. 2022. PMID: 35051649. doi:10.1016/j.cgh.2022.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。